Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214380 · ClinicalTrials.gov registry record · Phase 3
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 933
- Enrollment target
NCT03214380 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 933 participants.
The verdict
NCT03214380, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 933 participants
- Enrollment target
Study Summary
The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
Interventions
- DRUG Metformin
- DRUG Insulin Glargine
- DRUG Insulin Degludec
- DRUG Insulin Lispro
- DRUG LY900014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 933 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03214380
The ClinicalTrials.gov registry entry for NCT03214380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 933 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT03214380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03214380 about?
NCT03214380 is a clinical study titled "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes". The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).
What is the current status of trial NCT03214380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 933 participants. The study started on 2017-07-14. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT03214380?
The interventions under investigation include: Metformin (DRUG), Insulin Glargine (DRUG), Insulin Degludec (DRUG), Insulin Lispro (DRUG), LY900014 (DRUG).
Who is sponsoring clinical trial NCT03214380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.